Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Sage Therapeutics Inc shares valued at $41,441 were purchased by JONAS JEFFREY M on Dec 10 ’24. At $5.53 per share, JONAS JEFFREY M acquired 7,500 shares.
As published in a research note from RBC Capital Mkts on November 21, 2024, Sage Therapeutics Inc [SAGE] has been rated up from an Underperform to a Sector perform and the price target has been revised to $4. As of October 04, 2024, RBC Capital Mkts has decreased its “an Outperform” rating to a “Sector perform” for SAGE. Earlier on July 30, 2024, TD Cowen downgraded its rating. Their new recommendation was “a Hold” for SAGE stock which previously was a “a Buy”.
Analyzing SAGE Stock Performance
During the last five days, there has been a surge of approximately 19.15%. Over the course of the year, Sage Therapeutics Inc shares have jumped approximately 28.36%. Shares of the company reached a 52-week high of $7.88 on 01/13/25 and a 52-week low of $5.40 on 01/02/25. A 50-day SMA is recorded $5.71, while a 200-day SMA reached $9.16. Nevertheless, trading volume fell to 6.05 million shares from 4.4 million shares the previous day.
Support And Resistance Levels for Sage Therapeutics Inc (SAGE)
According to the 24-hour chart, there is a support level at 6.71, which, if violated, would cause prices to drop to 6.46. In the upper region, resistance lies at 7.26. The next price resistance is at 7.56. RSI (Relative Strength Index) is 61.54 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.02, which suggests the price will increase in the coming days. Percent R is at 34.47%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
